Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
RSLS 
ReShape Lifesciences Inc (RSLS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: RSLS (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $1
1 Year Target Price $1
| 0 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -26.54% | Avg. Invested days 69 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 9.35M USD | Price to earnings Ratio - | 1Y Target Price 1 |
Price to earnings Ratio - | 1Y Target Price 1 | ||
Volume (30-day avg) 1 | Beta 1.9 | 52 Weeks Range 7.48 - 1212.99 | Updated Date 08/23/2025 |
52 Weeks Range 7.48 - 1212.99 | Updated Date 08/23/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -830.44 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-08-14 | When - | Estimate - | Actual -9 |
Profitability
Profit Margin -48.26% | Operating Margin (TTM) -165.23% |
Management Effectiveness
Return on Assets (TTM) -53.5% | Return on Equity (TTM) -120.16% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 35026852 | Price to Sales(TTM) 1.3 |
Enterprise Value 35026852 | Price to Sales(TTM) 1.3 | ||
Enterprise Value to Revenue 4.88 | Enterprise Value to EBITDA -0.02 | Shares Outstanding 2385960 | Shares Floating 737812 |
Shares Outstanding 2385960 | Shares Floating 737812 | ||
Percent Insiders 10.63 | Percent Institutions 1.35 |
Upturn AI SWOT
ReShape Lifesciences Inc
Company Overview
History and Background
ReShape Lifesciences Inc (formerly EnteroMedics) was founded in 2002. Initially focused on neuromodulation for obesity, it evolved to focus on less invasive bariatric procedures. The company has faced financial challenges and strategic shifts over time.
Core Business Areas
- ReShape Vest System: A laparoscopically implanted device intended to support weight loss in obese patients. Not currently marketed in the US.
- ReShapeCare: A virtual care program designed to support patients undergoing weight loss procedures. Includes telehealth and patient support services.
- Obalon Balloon System: A swallowable intragastric balloon system for weight loss. ReShape acquired the Obalon assets in 2019.
Leadership and Structure
The company has a board of directors and an executive management team. The CEO is Paul F. Hickey. The organizational structure is typical of a small, publicly traded medical device company.
Top Products and Market Share
Key Offerings
- ReShapeCare: A virtual weight loss program. Revenue generation is dependent on successful patient enrollment and program adherence. Exact market share data is unavailable. Competitors include telehealth providers like Teladoc Health (TDOC) offering weight management programs, and other virtual weight loss programs.
- ReShape Vest System: A device implanted on the stomach. ReShape has suspended actively marketing this product. Competitors include Apollo Endosurgery (APEN, now part of Boston Scientific BSX), which offers bariatric surgery devices.
- Obalon Balloon System: An intragastric balloon. ReShape acquired the assets for this and aims to launch it in certain markets. Primary competitors include Apollo Endosurgery's Orbera intragastric balloon, and other balloon systems offered by international companies.
Market Dynamics
Industry Overview
The bariatric surgery and weight management market is growing due to increasing obesity rates and awareness of health risks. The market includes surgical procedures, medical devices, pharmaceuticals, and virtual care programs.
Positioning
ReShape Lifesciences Inc. aims to offer less invasive alternatives to traditional bariatric surgery. They focus on providing comprehensive weight loss solutions through devices and virtual care.
Total Addressable Market (TAM)
The global weight management market is estimated to be worth over $250 billion. Reshape Lifesciences aims to capture a share of the virtual care and less-invasive device segments of this market.
Upturn SWOT Analysis
Strengths
- Focus on less invasive weight loss solutions
- Virtual care platform (ReShapeCare)
- Acquisition of Obalon assets provides a potentially valuable product.
Weaknesses
- History of financial losses
- Limited market share in competitive markets
- Small company size limits resources
- Past regulatory hurdles with ReShape Vest System
Opportunities
- Expansion of ReShapeCare platform
- Increased adoption of telehealth services
- Launch of Obalon in new markets
- Potential partnerships with larger healthcare providers
Threats
- Competition from established bariatric surgery companies
- Regulatory changes impacting medical devices
- Economic downturn affecting consumer spending on weight loss programs
- Negative publicity or clinical trial results impacting device safety
Competitors and Market Share
Key Competitors
- BSX
- TDOC
- MDCO
Competitive Landscape
ReShape Lifesciences Inc faces intense competition from larger, more established companies. Their competitive advantage lies in less invasive approaches and virtual care, but they lack the resources and market reach of larger players. Market share percentage estimates are approximate.
Major Acquisitions
Obalon Therapeutics, Inc. (assets)
- Year: 2019
- Acquisition Price (USD millions): 2.4
- Strategic Rationale: Acquired the assets of Obalon to add a swallowable intragastric balloon system to their product portfolio.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been inconsistent due to strategic changes and financial difficulties.
Future Projections: Future projections are highly uncertain and dependent on successful commercialization of existing products and new initiatives.
Recent Initiatives: Focus on ReShapeCare platform, acquisition and intended relaunch of Obalon, and cost-cutting measures.
Summary
ReShape Lifesciences is a small company in the weight loss market facing considerable challenges. Their focus on less invasive solutions and virtual care is promising, but their financial history and small size create risk. Successful commercialization of ReShapeCare and Obalon is critical for their future, and will need to avoid competition.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings, press releases, market research reports, analyst reports.
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market share estimates are approximate and may vary based on different sources.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About ReShape Lifesciences Inc
Exchange NASDAQ | Headquaters Irvine, CA, United States | ||
IPO Launch date 2007-11-15 | CEO, President & Director Mr. Paul F. Hickey | ||
Sector Healthcare | Industry Medical Devices | Full time employees 17 | |
Full time employees 17 | |||
As of August 14, 2025, ReShape Lifesciences Inc. was acquired by Vyome Therapeutics Inc., in a reverse merger transaction. ReShape Lifesciences Inc. provides products and services that manage and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System to treat obesity and invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; Lap-Band 2.0 System, an adjustable postoperatively to increase or decrease the pressure to the band to optimize an individual's comfort and therapy effectiveness; and ReShape Calibration Tubes, that fits the lesser curvature of the stomach to reach the pylorus. It is involved in the development of the ReShape Obalon Balloon System, which consists of a swallowable capsule that tracks and displays the location of the balloon during placement; and the Diabetes Bloc-Stim Neuromodulation (DBSN) device, a technology that is in development for the treatment of type 2 diabetes mellitus. ReShape Lifesciences Inc. was founded in 2002 and is headquartered in Irvine, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.